Literature DB >> 940741

[Angioimmunoblastic lymphadenopathies with autoimmune anemia and polyclonal hyperimmunoglobulinemia].

G Flandrin.   

Abstract

The study concerned 13 cases of angio-immunoblastic lymphadenopathy. This systemic lymphoid disorder has been identified only recently and is surely more common than has been thought. It is characterised by specific changes in the lymph nodes, which are infiltrated by plasmocytic and immunoblastic cells, associated with a marked degree of vascular neogenesis. This anatomical involvement is accompanied by numerous immunological manifestations, the most important of which are a positive Coombs test and a polyclonal hyperimmunoglobulinaemia. Despite the severe course of the disorder, its benign or malignant nature is uncertain and the therapeutic approach remains a subject of discussion.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 940741

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  5 in total

1.  Haematological features of angioimmunoblastic lymphadenopathy with dysproteinaemia.

Authors:  R L Brearley; J Chapman; M H Cullen; M A Horton; A G Stansfeld; A H Waters
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

2.  Angioimmunoblastic lymphadenopathy, immunoblastic sarcoma of B cells. Animal model: autoimmune-prone inbred Armenian hamster.

Authors:  G Yerganian; H J Gagnon; A Battaglino
Journal:  Am J Pathol       Date:  1978-04       Impact factor: 4.307

3.  Arthritis and angioimmunoblastic lymphadenopathy.

Authors:  P G Davies; J N Fordham
Journal:  Ann Rheum Dis       Date:  1983-10       Impact factor: 19.103

4.  Angioimmunoblastic lymphadenopathy associated with polyarthritis.

Authors:  R S Rothwell; M J Mant; P Davis
Journal:  Ann Rheum Dis       Date:  1980-08       Impact factor: 19.103

5.  Rheumatoid arthritis associated with bronchiolitis obliterans and immunoblastic sarcoma.

Authors:  R Pieters; J Martens; J Dequeker
Journal:  Clin Rheumatol       Date:  1982-03       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.